Nj State Employees Deferred Compensation Plan Xenon Pharmaceuticals Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $877 Million
- Q3 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 25,000 shares of XENE stock, worth $957,499. This represents 0.11% of its overall portfolio holdings.
Number of Shares
25,000
Previous 25,000
-0.0%
Holding current value
$957,499
Previous $782,000
28.26%
% of portfolio
0.11%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
225Shares Held
73.1MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$207 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$166 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$138 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$137 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$122 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.38B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...